MiRXES
Diagnostica dell'RNA, test di screening del cancro e saggi molecolari.
MiRXES produce strumenti diagnostici per l'RNA, test di screening del cancro e test molecolari dalle sue sedi a Singapore. L'azienda fornisce sistemi sanitari, laboratori, partner OEM o clienti esportatori regolamentati nei suoi mercati primari quotati.
- Type
- brand seeking distribution
- Location
- Singapore
- Founded
- 2014
- Website
- mirxes.com
- Categories
- Forniture medicali e sanitarie
- Markets
- Singapore, Stati Uniti, Cina, Giappone
Verified facts
- corporate-mail-on-domain (green), checked 2026-08-09 Mail server of the company domain
- domain-registered (green), checked 2026-08-09 Domain registry record
- sanctions-clear (green), checked 2026-08-09 OpenSanctions
- debarment-clear (green), checked 2026-08-09 OpenSanctions
Claimed certifications
- ISO 13485, Medical Devices Quality IAF CertSearch
- CE Marking EU NANDO (notified bodies)
Import rules for these goods
- Medical devices sold in the EU must carry CE marking under the Medical Device Regulation (EU) 2017/745, with a conformity assessment matched to the device risk class. European Commission (MDR)
- For the US market, the maker must have an FDA device establishment registration and product listing; most instruments also need 510(k) premarket clearance. US FDA (devices)